Patients with relapsed acute myelogenous leukemia (AML) have a uniformly grim prognosis;only 13-40% achieves a complete response (CR/CRi) with currently available salvage chemotherapy regimens. Long-term survival can only be achieved by those who proceed to an allogeneic cell transplant after achieving a CR2. In spite of advances in our understanding of the biology of both AML and relapsed AML, there have been no significant improvements in either treatments or outcomes in the past 10-20 years. This suggests the need for innovative new approaches to overcome inherent biologic resistance of relapsed AML. We hypothesize that targeting the interaction of AML with the bone marrow (BM) microenvironment will overcome the acquired resistance factors inherent in relapsed AML and result in improved CR rates and overall outcomes. We and others have shown that the BM microenvironment provides an important protective effect against genotoxic stresses such as chemotherapy and that physical interruption of this interaction render AML cells sensitive to chemotherapy in vitro and in vivo. We propose to target the CXCR4-SDF-1 axis using a small molecule bicyclam, AMD3100 in conjunction with Granulocyte Colony Stimulating Factor (G-CSF), to promote rapid and sustained release of AML blasts from the BM microenvironment in patients with relapsed AML.
In Aim 1 we will perform a phase I/II clinical trial in patients with relapsed AML. G-CSF+AMD3100 will be administered prior to mitoxantrone-etoposide-high dose Ara-C (MEC) salvage chemotherapy to optimally mobilize leukemic blasts, thus sensitizing the AML blasts to MEC chemotherapy. We will assess the safety and toxicities of G- CSF+AMD3100, their impact on multi-lineage hematopoietic recovery and, most importantly, on CR rates.
In Aim 2 we will measure the magnitude of AML mobilization after G-CSF +AMD3100 administration and attempt to characterize the phenotype and cell cycle status of AML blasts and primitive (CD34+/CD38-) subsets of AML before and after G-CSF+AMD3100 treatment. In addition we will functionally assess the impact of G- CSF+AMD3100 on mobilizing Leukemia Stem Cells (LSCs) using in vitro LTC-IC and in vivo NOD-SCID repopulating cell (SRC) assays.
In Aim 3 we will use a novel and informative models of mouse AML and human ALL to explore the role of small molecule inhibitors of two other critical axes (VLA-4/VCAM-1 and Selectin/Selectin Ligand) on normal and leukemia stem cell mobilization and homing to the BM. The effects of these small molecules will be tested alone or in combination with CXCR4 blocking agents (AMD3100, 070, G- CSF and ALT1188). VLA-4 and pan-selectin inhibitors will be used in these models alone or in combination to determine if they also can be used to sensitize leukemic cells to chemotherapy in vivo. These studies will provide insights on the effect of disrupting AML-BM microenvironment interactions using AMD3100, G-CSF and other small molecules in the future. This approach may represent a simple and non-toxic way of increasing chemotherapy sensitivity and overcoming inherent genetic and epigenetic resistance factors associated with AML thus improving outcomes of patients with relapsed and resistant AML.
Acute myelogenous leukemia (AML) represents a diverse group of diseases with diverse genetic and epigenetic abnormalities. Prognosis of patients who relapse or who have refractory disease is dismal. New approaches are needed which both target genetic abnormalities associated with initiation and progression of the disease and interrupt common pathways that support the survival and quiescent state of leukemic cells. We propose to use G-CSF plus AMD3100 as well as other novel small molecule inhibitors of three critical pathways associated with homing of AML blasts to the bone marrow thus rendering these cells more sensitive to chemotherapy. We hypothesize that pharmacologic interruption of the tethers that bind AML blasts to the bone marrow will sensitize these cells to chemotherapy and improve remission rates and long term disease free survival.
|Ghobadi, Armin; Rettig, Michael P; Holt, Matthew S et al. (2018) Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice. Blood 131:2594-2596|
|Kotagiri, Nalinikanth; Cooper, Matthew L; Rettig, Michael et al. (2018) Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer. Nat Commun 9:275|
|Ghobadi, Armin; Fiala, Mark A; Ramsingh, Giridharan et al. (2017) Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 23:1072-1077|
|Schroeder, Mark A; Rettig, Michael P; Lopez, Sandra et al. (2017) Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood 129:2680-2692|
|Karpova, Darja; Ritchey, Julie K; Holt, Matthew S et al. (2017) Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells. Blood 129:2939-2949|
|Uy, G L; Rettig, M P; Stone, R M et al. (2017) A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia. Blood Cancer J 7:e542|
|Kim, Aimee G; Vrecenak, Jesse D; Boelig, Matthew M et al. (2016) Enhanced in utero allogeneic engraftment in mice after mobilizing fetal HSCs by ?4?1/7 inhibition. Blood 128:2457-2461|
|Uy, Geoffrey L; Hsu, Yen-Michael S; Schmidt, Amy P et al. (2015) Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. Leuk Res 39:1437-42|
|Fadini, Gian Paolo; Fiala, Mark; Cappellari, Roberta et al. (2015) Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor. Diabetes 64:2969-77|
|Al-Hussaini, Muneera; DiPersio, John F (2014) Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic. Expert Rev Hematol 7:439-64|
Showing the most recent 10 out of 14 publications